Citi initiated coverage of Amgen (AMGN) with a Neutral rating and $335 price target The company’s growth picture hinges on MariTide clinical success and to a lesser degree, the trajectory for several newer products, the analyst tells investors in a research note. The firm says MariTide likely will need to demonstrate monthly dosing, 15%-20% minimum weight loss, and less than 10% discontinuations along with benign safety, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMGN:
- Amgen (NASDAQ:AMGN) Stock Rises Again After Bone Density Data Leak
- Amgen issues statement regarding MariTide Phase 1 data
- Amgen’s AMG-133 Phase 1 bone data ‘seems non-issue,’ says Jefferies
- Amgen MariTide bone mineral density loss data ‘leaked,’ says Cantor Fitzgerald
- Amgen, AstraZeneca announce top-line results from WAYPOINT trial
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
